A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma.
Saved in:
| Title: | A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma. |
|---|---|
| Authors: | Shepard DR; Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue/Desk R35, Cleveland, OH 44195, USA. shepard@ccf.org, Cooney MM, Elson P, Bukowski RM, Dreicer R, Rini BI, Garcia JA |
| Source: | Investigational new drugs [Invest New Drugs] 2012 Feb; Vol. 30 (1), pp. 364-7. Date of Electronic Publication: 2010 Aug 14. |
| Publication Type: | Clinical Trial, Phase II; Journal Article |
| Journal Info: | Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 20711630 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Shepard+DR%22">Shepard DR</searchLink>; Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue/Desk R35, Cleveland, OH 44195, USA. shepard@ccf.org<br /><searchLink fieldCode="AU" term="%22Cooney+MM%22">Cooney MM</searchLink><br /><searchLink fieldCode="AU" term="%22Elson+P%22">Elson P</searchLink><br /><searchLink fieldCode="AU" term="%22Bukowski+RM%22">Bukowski RM</searchLink><br /><searchLink fieldCode="AU" term="%22Dreicer+R%22">Dreicer R</searchLink><br /><searchLink fieldCode="AU" term="%22Rini+BI%22">Rini BI</searchLink><br /><searchLink fieldCode="AU" term="%22Garcia+JA%22">Garcia JA</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%228309330%22">Investigational new drugs</searchLink> [Invest New Drugs] 2012 Feb; Vol. 30 (1), pp. 364-7. <i>Date of Electronic Publication: </i>2010 Aug 14. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase II; Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer%22">Springer </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8309330 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1573-0646 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201676997%22">01676997 </searchLink><i>NLM ISO Abbreviation: </i>Invest New Drugs <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=20711630 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s10637-010-9516-1 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 364 Titles: – TitleFull: A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Shepard DR – PersonEntity: Name: NameFull: Cooney MM – PersonEntity: Name: NameFull: Elson P – PersonEntity: Name: NameFull: Bukowski RM – PersonEntity: Name: NameFull: Dreicer R – PersonEntity: Name: NameFull: Rini BI – PersonEntity: Name: NameFull: Garcia JA IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 02 Text: 2012 Feb Type: published Y: 2012 Identifiers: – Type: issn-electronic Value: 1573-0646 Numbering: – Type: volume Value: 30 – Type: issue Value: 1 Titles: – TitleFull: Investigational new drugs Type: main |
| ResultId | 1 |
